Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | NT5E | P21589 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.60 |
| ▸ | PDE2A | O00408 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399918 | 0.89 | ADORA2A (0.76) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL29135435 | 0.89 | ADORA2A (0.76) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL29100469 | 0.89 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL12150807 | 0.89 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL29533297 | 0.89 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL12031300 | 0.89 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL12300482 | 0.89 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL1527213 | 0.89 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL1527211 | 0.89 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL20473787 | 0.89 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | AGO2, BCDIN3D, TRDMT1 | LMNA 866/4885NT5E 344/4885HIF1A 1479/4885 |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, RNGTT, NSUN2 | LMNA 3915/4885NT5E 32/4885HIF1A 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.